Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
PAMIDRONATE DISODIUM PENTAHYDRAT
Novartis Pharmaceuticals UK Ltd
PAMIDRONATE DISODIUM PENTAHYDRAT
30 Milligram
Pdr/Conc/Soln for Infus
Product subject to prescription which may not be renewed (A)
Authorised
0000-00-00
INFORMATION FOR THE MEDICAL PROFESSIONALS 1 NAME OF THE MEDICINAL PRODUCT Aredia 90mg Powder and solvent for concentrate for solution for infusion Aredia 30mg Powder and solvent for concentrate for solution for infusion Pamidronate disodium 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 30mg or 90mg vial contains lyophilised pamidronate disodium pentahydrate equivalent to 30mg or 90mg of pamidronate disodium anhydrous. A 10ml ampoule of water for injections is supplied with each vial. When reconstituted, the concentration is 3mg/ml or 9mg/ml. Further dilution is required. For full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder and solvent for concentrate for solution for infusion. White, lyophilized mass. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the treatment of tumour-induced osteolysis with or without tumour-induced hypercalcaemia. For the treatment of Paget’s disease of bone. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _DIRECTIONS FOR USE _ For intravenous infusion Aredia must never be given as a bolus injection (see section 4.4 Special warnings and precautions for use). Aredia should always be diluted before use and administered as a slow intravenous infusion. Novartis Page 2 BPL May 2014 Aredia _PREPARATION OF INFUSION _ This is a two step procedure: 1. Using aseptic technique, Aredia dry powder 30mg or 90mg should be dissolved in 10ml of Water for Injections Ph.Eur. It is important that the dry substance is completely dissolved before proceeding to step 2. 2. The reconstituted solution is withdrawn for dilution. Reconstituted solution of Aredia from powder in vials should be diluted in a calcium-free infusion solution (0.9% sodium chloride or 5% glucose). Aredia must not be mixed w Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Aredia 30mg powder and solvent for concentrate for solution for infusion. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 30 mg vial contains lyophilised pamidronate disodium pentahydrate equivalent to 30 mg pamidronate disodium anhydrous. A 10 ml ampoule of water for injections is supplied with each vial. When reconstituted, the concentration is 3mg/ml. Further dilution is required. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder and solvent for concentrate for solution for infusion (Powder and solvent for sterile concentrate) White, lyophilized mass. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the treatment of tumour-induced osteolysis with or without tumour-induced hypercalcaemia. For the treatment of Paget’s disease of bone. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _DIRECTIONS FOR USE:_ For intravenous infusion Aredia must never be given as a bolus injection (see section 4.4 Special warnings and precautions for use). Aredia should always be diluted before use and administered as a slow intravenous infusion. _PREPARATION OF INFUSION:_ This is a two step procedure: 1. Using aseptic technique, Aredia dry powder 30mg should be dissolved in 10 ml of Water for Injections Ph.Eur. It is important that the dry substance is completely dissolved before proceeding to step 2. 2. The reconstituted solution is withdrawn for dilution. Reconstituted solution of Aredia from powder in vials should be diluted in a calcium-free infusion solution (0.9% sodium chloride or 5% glucose). Aredia must not be mixed with calcium or other divalent cation-containing solutions such as Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other Read the complete document